人非小细胞肺腺癌细胞 NCI-H157
BLUEFBIO™ Product Sheet
|
细胞名称 |
人非小细胞肺腺癌细胞NCI-H157 |
|
|
|
货物编码 |
BFN60700213 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研用途 1类 |
||
|
培养体系 |
DMEM高糖培养基（Hyclone）+10%胎牛血清（Gibco）+1%双抗（Hyclone） |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人非小细胞肺腺癌细胞NCI-H157细胞由青旗（上海）生物技术发展有限公司于2016年引进自ATCC（CRL-5802） |
||
|
注释 |
Problematic cell line: Contaminated. NCI-H157 and NCI-H1264 have been shown to be identical. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00412. Doubling time: 53 hours (in RPMI 1640 + 10% FBS), 90 hours (in ACL-3 + BSA) (PubMed=3940644). Omics: Deep proteome analysis. Omics: miRNA expression profiling. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. |
||
|
STR信息 |
Amelogenin：X；CSF1PO：12；D13S317：12；D16S539：12，13；D18S51：13，15；D19S433：11，13；D21S11：32；D2S1338：21，22；D3S1358：17，18；D5S818：10，13；D7S820：12；D8S1179：14，16；FGA：22，23；TH01：7，9；TPOX：6，12；vWA：15； |
||
|
参考文献 |
PubMed=6148444; DOI=10.1093/jnci/73.4.801 Morstyn G., Russo A., Carney D.N., Karawya E., Wilson S.H., Mitchell J.B. Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines. J. Natl. Cancer Inst. 73:801-807(1984)
PubMed=3940644 Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46:798-806(1986)
PubMed=1311061 Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171-180(1992)
PubMed=1563005 Giaccone G., Battey J., Gazdar A.F., Oie H.K., Draoui M., Moody T.W. Neuromedin B is present in lung cancer cell lines. Cancer Res. 52:2732s-2736s(1992)
PubMed=8626706; DOI=10.1074/jbc.271.19.11477 Quinn K.A., Treston A.M., Unsworth E.J., Miller M.-J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J. Biol. Chem. 271:11477-11483(1996)
PubMed=8806092; DOI=10.1002/jcb.240630505 Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L. NCI-Navy Medical Oncology Branch cell line data base. J. Cell. Biochem. 63 Suppl. 24:32-91(1996)
PubMed=9649128; DOI=10.1038/bjc.1998.361 Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br. J. Cancer 77:2162-2170(1998)
PubMed=11005564; DOI=10.1038/sj.neo.7900094 Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M., Yokota J. Mutation and expression of the DCC gene in human lung cancer. Neoplasia 2:300-305(2000)
PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0 Luk C., Tsao M.-S., Bayani J., Shepherd F., Squire J.A. Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 125:87-99(2001)
PubMed=12068308; DOI=10.1038/nature00766 Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417:949-954(2002)
PubMed=19472407; DOI=10.1002/humu.21028 Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 30:1199-1206(2009)
PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010)
PubMed=20624269; DOI=10.1186/1756-9966-29-75 Du L., Schageman J.J., Irnov I., Girard L., Hammond S.M., Minna J.D., Gazdar A.F., Pertsemlidis A. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J. Exp. Clin. Cancer Res. 29:75-75(2010)
PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112 Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., Masrorpour F., Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2:798-811(2012)
PubMed=23381221; DOI=10.3892/or.2013.2266 Suzuki M., Shiraishi K., Eguchi A., Ikeda K., Mori T., Yoshimoto K., Ohba Y., Yamada T., Ito T., Baba Y., Baba H. Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer. Oncol. Rep. 29:1308-1314(2013)
PubMed=25120651; DOI=10.3892/ol.2014.2234 Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K., Shibata H., Ito T., Baba Y., Baba H. Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol. Lett. 8:1025-1030(2014)
PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003 Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C., Daub H. Comparative proteome analysis across non-small cell lung cancer cell lines. J. Proteomics 130:1-10(2016) |
||
验收细胞注意事项
1、收到人非小细胞肺腺癌细胞NCI-H157细胞，请查看瓶子是否有破裂，培养基是否漏出，是否浑浊，如有请尽快联系。
2、收到人非小细胞肺腺癌细胞NCI-H157细胞，如包装完好，请在显微镜下观察细胞。,由于运输过程中的问题，细胞培养瓶中的贴壁细胞有可能从瓶壁中脱落下来，显微镜下观察会出现细胞悬浮的情况，出现此状态时，请不要打开细胞培养瓶，应立即将培养瓶置于细胞培养箱里静止 3-5 小时左右，让细胞先稳定下，再于显微镜下观察，此时多数细胞会重新贴附于瓶壁。如细胞仍不能贴壁，请用台盼蓝染色法鉴定细胞活力，如台盼蓝染色证实细胞活力正常请按悬浮细胞的方法处理。
3、收到人非小细胞肺腺癌细胞NCI-H157细胞后，请镜下观察细胞，用恰当方式处理细胞。若悬浮的细胞较多，请离心收集细胞，接种到一个新的培养瓶中。弃掉原液，使用新鲜配制的培养基，使用进口胎牛血清。刚接到细胞，若细胞不多时 血清浓度可以加到 15％去培养。若细胞迏到 80%左右 ，血清浓度还是在 10％。
4、收到人非小细胞肺腺癌细胞NCI-H157细胞时如无异常情况 ，请在显微镜下观察细胞密度，如为贴壁细胞，未超过80%汇合度时，将培养瓶中培养基吸出，留下 5-10ML 培养基继续培养：超过 80%汇合度时，请按细胞培养条件传代培养。如为悬浮细胞，吸出培养液，1000 转/分钟离心 3 分钟，吸出上清，管底细胞用新鲜培养基悬浮细胞后移回培养瓶。
5、将培养瓶置于 37℃培养箱中培养，盖子微微拧松。吸出的培养基可以保存在灭菌过的瓶子里，存放于 4℃冰箱，以备不时之需。
6、24 小时后，人非小细胞肺腺癌细胞NCI-H157细胞形态已恢复并贴满瓶壁，即可传代。（贴壁细胞）将培养瓶里的培养基倒去，加 3-5ml（以能覆盖细胞生长面为准）PBS 或 Hanks’液洗涤后弃去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化时间以具体细胞为准，一般 1-3 分钟，不超过 5 分钟。可以放入37℃培养箱消化。轻轻晃动瓶壁，见细胞脱落下来，加入 3-5ml 培养基终止消化。用移液管轻轻吹打瓶壁上的细胞，使之完全脱落，然后将溶液吸入离心管内离心，1000rpm/5min。弃上清，视细胞数量决定分瓶数，一般一传二，如细胞量多可一传三，有些细胞不易传得过稀，有些生长较快的细胞则可以多传几瓶，以具体细胞和经验为准。（悬浮细胞）用移液管轻轻吹打瓶壁，直接将溶液吸入离心管离心即可。
7、贴壁细胞 ，悬浮细胞。严格无菌操作。换液时，换新的细胞培养瓶和换新鲜的培养液，37℃，5%CO2 培养。
特别提醒： 原瓶中培养基不宜继续使用，请更换新鲜培养基培养。
